Exane Derivatives’s Ligand Pharmaceuticals LGND Stock Holding History

Exane Derivatives’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,154	Closed	-$65.7K	–	725
2019 Q4	$65.7K	Hold	1,154	–	–	0.01%	348
2019 Q3	$71.7K	Hold	1,154	–	–	0.01%	344
2019 Q2	$82.2K	Hold	1,154	–	–	0.01%	351
2019 Q1	$90.5K	Buy	1,154 +734	+175%	+$55.6K	0.02%	306
2018 Q4	$35.5K	Buy	+420	New	+$44.8K	0.01%	396

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Exane Derivatives's LGND Position: Q1 2020 in Review

Exane Derivatives sold out of Ligand Pharmaceuticals (LGND) in Q1 2020, closing a stake of 1,154 shares — an estimated $65.7K sold.

Exane Derivatives first reported a position in LGND in Q4 2018 and held it in 5 quarters. The position peaked at $90.5K in Q1 2019. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2020.

Exane Derivatives reported no remaining Ligand Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Exane Derivatives sold 1,154 Ligand Pharmaceuticals shares in Q1 2020, an estimated $65.7K.
Exane Derivatives first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 5 quarters.
Exane Derivatives's Ligand Pharmaceuticals position peaked at $90.5K in Q1 2019.
262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2020.

Based on Exane Derivatives's 13F filing for Q1 2020, filed 17 Apr 2020.